Northwest Biotherapeutics, Inc Share Price OTC Bulletin Board
Equities
US66737P5017
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
|
10/05 | Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
21/03 | Northwest Biotherapeutics, Inc. Appoints Pat Sarma to Its Board of Directors | CI |
Sales 2022 | 1.68M 141M | Sales 2023 | 1.93M 161M | Capitalization | 822M 68.65B |
---|---|---|---|---|---|
Net income 2022 | -105M -8.77B | Net income 2023 | -62M -5.18B | EV / Sales 2022 | 505 x |
Net Debt 2022 | 19.29M 1.61B | Net Debt 2023 | 43.43M 3.63B | EV / Sales 2023 | 448 x |
P/E ratio 2022 |
-7.59
x | P/E ratio 2023 |
-11.7
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 90.84% |
Managers | Title | Age | Since |
---|---|---|---|
Linda Powers
CEO | Chief Executive Officer | 68 | 17/07/17 |
Alton Boynton
FOU | Founder | 79 | 18/96/18 |
Marnix Bosch
CTO | Chief Tech/Sci/R&D Officer | 65 | 01/00/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Alton Boynton
FOU | Founder | 79 | 18/96/18 |
Linda Powers
CEO | Chief Executive Officer | 68 | 17/07/17 |
Navid Malik
BRD | Director/Board Member | 55 | 01/12/01 |
1st Jan change | Capi. | |
---|---|---|
+16.85% | 122B | |
+22.03% | 116B | |
+22.18% | 27.03B | |
-21.25% | 20.36B | |
-16.89% | 16.43B | |
-18.31% | 15.91B | |
-44.74% | 15.6B | |
+62.75% | 14.94B | |
+3.10% | 13.59B |